Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention.
<h4>Background</h4>The safety and efficacy profile of bivalirudin has not been examined in a randomised controlled trial of patients undergoing rescue PCI.<h4>Objectives</h4>We conducted an open-label, multi-centre, randomised controlled trial to compare bivalirudin with hepa...
Enregistré dans:
Auteurs principaux: | Amir Faour, Nicholas Collins, Trent Williams, Arshad Khan, Craig P Juergens, Sidney Lo, Darren L Walters, Derek P Chew, John K French |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3da8d2a609f849eabf83cc2f6167f89e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention
par: Amir Faour, et autres
Publié: (2021) -
Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
par: Senjie Li, et autres
Publié: (2021) -
Assessing plasminogen activation potential with global fibrinolytic assays
par: Tetsumei Urano, et autres
Publié: (2020) -
Percutaneous Endoscopic Gastrostomy Tube Gone Wrong: Endoscopic Closure to the Rescue
par: Jahnvi Dhar, et autres
Publié: (2021) -
Microbial Fibrinolytic Enzymes as Anti-Thrombotics: Production, Characterisation and Prodigious Biopharmaceutical Applications
par: Chhavi Sharma, et autres
Publié: (2021)